Literature DB >> 12390540

Inclusion of Vpr accessory gene in a plasmid vaccine cocktail markedly reduces Nef vaccine effectiveness in vivo resulting in CD4 cell loss and increased viral loads in rhesus macaques.

K Muthumani1, M Bagarazzi, D Conway, D S Hwang, V Ayyavoo, D Zhang, K Manson, J Kim, J Boyer, D B Weiner.   

Abstract

We compared the immunogenicity of plasmid vaccines containing multiple human immunodeficiency virus (HIV) antigens and found that covaccination with plasmids expressing HIV-1 14 kDa vpr gene product profoundly reduces antigen-specific CD8-mediated cytotoxic T-cell activity (CTL). Interestingly, Th1 type responses against codelivered antigens (pGag-Pol, pNef, etc.) encoded by the plasmid vaccines were suppressed. This suggested that vpr might compromise CD8 T-cell immunity in vivo during infection. A pilot primate vaccine study was designed to test the hypothesis to compare the following groups: unvaccinated controls, animals vaccinated without simean immunodeficiency virus (SIV)-Nef antigen plasmid, and animals covaccinated with the identical plasmid antigen and a plasmid construct encoding SIV Vpr/Vpx. Animals were subsequently challenged intrarectally with pathogenic SIVmac251 after the final vaccination of a multiple immunization protocol. Control animals were all infected and exhibited high viral loads and rapid CD4+ T-cell loss. In contrast, the Nef plasmid-vaccinated animals were also infected but exhibited preservation of CD4+ T-cells and a multilog reduction in viral load compared with controls. Animals covaccinated multiple times with the Nef vaccine and pVpr/Vpx plasmid suffered rapid and profound loss of CD4+ T-cells. These results have important implications for the design of multicomponent and particle vaccines for HIV-1 as well as for our understanding of HIV/SIV pathogenesis in vivo.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12390540     DOI: 10.1034/j.1600-0684.2002.02004.x

Source DB:  PubMed          Journal:  J Med Primatol        ISSN: 0047-2565            Impact factor:   0.667


  6 in total

Review 1.  The role of HIV-1 Vpr in promoting the infection of nondividing cells and in cell cycle arrest.

Authors:  Hamayun J Sharifi; Andrea M Furuya; Carlos M C de Noronha
Journal:  Curr Opin HIV AIDS       Date:  2012-03       Impact factor: 4.283

Review 2.  The functions of the HIV1 protein Vpr and its action through the DCAF1.DDB1.Cullin4 ubiquitin ligase.

Authors:  Laurieann Casey; Xiaoyun Wen; Carlos M C de Noronha
Journal:  Cytokine       Date:  2010-03-27       Impact factor: 3.861

3.  Inhibition of NF-κB activity by HIV-1 Vpr is dependent on Vpr binding protein.

Authors:  Michael Kogan; Satish Deshmane; Bassel E Sawaya; Edward J Gracely; Kamel Khalili; Jay Rappaport
Journal:  J Cell Physiol       Date:  2013-04       Impact factor: 6.384

Review 4.  HIV-1 accessory protein Vpr: relevance in the pathogenesis of HIV and potential for therapeutic intervention.

Authors:  Michael Kogan; Jay Rappaport
Journal:  Retrovirology       Date:  2011-04-13       Impact factor: 4.602

5.  The immunosuppressive properties of the HIV Vpr protein are linked to a single highly conserved residue, R90.

Authors:  Irina Tcherepanova; Aijing Starr; Brad Lackford; Melissa D Adams; Jean-Pierre Routy; Mohamed Rachid Boulassel; David Calderhead; Don Healey; Charles Nicolette
Journal:  PLoS One       Date:  2009-06-10       Impact factor: 3.240

6.  T-Cell Signaling in HIV-1 Infection.

Authors:  Wasim Abbas; Georges Herbein
Journal:  Open Virol J       Date:  2013-07-26
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.